miDiagnostics, which is using an Imec-invented IC technology  to bring lab-quality tests with built-in connectivity direct to the patient and clinician regardless of location, has secured a €14m investment round.

The round was supported by existing shareholders as well as leading life science and tech investors Dr. Rudi Pauwels and Dr. Ir. Urbain Vandeurzen.

The funds will be used to accelerate the development of miDiagnostics’ proprietary nanofluidic processor on a chip, and to prepare it for industrial-scale manufacturing.

miDiagnostics’ unique technology will enable fast, comprehensive and cost-effective analysis of a wide range of health conditions. The technology has potential in multiple settings:

Monitoring chronic patients at home;
Fast screening for physicians or remote health centers in developing countries; and
Widespread monitoring during pandemics

miDiagnostics’ technology was invented by Imec and Johns Hopkins University.

miDiagnostics is currently working with NASA to evaluate its technology under simulated zero gravity conditions.

“We are delighted to see miDiagnostics’ significant progress towards bringing Imec originated technology to the wider market,” says Imec CEO Luc van den Hove (pictured), “we welcome this financing round and are pleased to see the engagement of Urbain, Rudi alongside existing shareholders to support the further development of the business. I am convinced that this unique microfluidics technology will create a revolution in the diagnostics industry, similar to what the micro-processor has done for the computer industry.”